⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 16 in last 7 days 🍎 Food: 193 in last 7 days 🧸 Products: 48 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 4 hours ago ⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 16 in last 7 days 🍎 Food: 193 in last 7 days 🧸 Products: 48 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 4 hours ago
🛡️ EUSW
💊 Medicines 🍎 Food 🧸 Products 🔎 Search
📊 Data
🏷 Brands 🌍 Countries ℹ️ About ✉ Unsubscribe
🇬🇧
🇬🇧 English 🇳🇱 Nederlands 🇫🇷 Français 🇩🇪 Deutsch 🇪🇸 Español 🇮🇹 Italiano 🇵🇹 Português 🇵🇱 Polski 🇸🇪 Svenska 🇷🇴 Română 🇨🇿 Čeština 🇫🇮 Suomi 🇩🇰 Dansk
💊 Medicine AT January 28, 2026

Daunoblastin 20 mg Pulver zur Herstellung einer Infusions- oder Injektionslösung 20 mg

📷 Wikipedia: Daunorubicin · Source
Daunoblastin 20 mg Pulver zur Herstellung einer Infusions- oder Injektionslösung 20 mg
📷 Wikipedia: Daunorubicin · Source
Daunoblastin 20 mg powder for preparing an infusion or injection solution 20 mg Parallel export is banned. Supply is limited due to manufacturing capacity issues.
✅
Resolved by agency
The issuing agency has confirmed this medicine alert is over — the underlying issue was addressed. Originally reported 120 days ago.
📈 Timeline
1 days in total
May 18, 2026 May 19, 2026

What is this? Daunoblastin is a medicine used in cancer treatment. It comes as a powder that is mixed into a drip or injection.

What's happening? There is a limited supply of this medicine in Austria. A ban on exporting it is in place.

Does this affect me? If you are receiving cancer treatment with this medicine in Austria, you may be affected.

What should I do? Talk to your pharmacist or doctor about your treatment options.

🤖 This plain-language summary is automatically generated from the official agency notice using AI. It is for general information only — not medical advice. For decisions about your health, always consult a pharmacist or doctor and read the official source linked below.

🔬 Medical / technical details (for professionals)
Active substance(s)
DAUNORUBICIN HYDROCHLORID
Agency-published detail

🚫 Parallel export ban active · ATC: L01DB02 · Reason: Kapazitätsengpässe bei der Herstellung · Marketing authorisation holder: Pfizer Corporation Austria Ges.m.b.H., Floridsdorfer Hauptstraße 1, 1210 Wien, Österreich · Affected packs: 1 Stück Schachtel, Durchstechflasche [eingeschränkt verfügbar, since 2026-01-28]

First published
January 28, 2026
Last refreshed by us
1 week ago
Severity (as classified)
High
Official source
https://medikamente.basg.gv.at/en/medicine-shortage

All information on this page comes from the official agency notice. We translate and summarise it; we don't add or edit facts.

❓ Frequently asked questions

▸ What is this medicine shortage alert about?
Daunoblastin 20 mg Pulver zur Herstellung einer Infusions- oder Injektionslösung 20 mg. Daunoblastin 20 mg powder for preparing an infusion or injection solution 20 mg Parallel export is banned. Supply is limited due to manufacturing capacity issues.
▸ When was this alert issued?
This alert was issued on January 28, 2026 by BASG (Austria).
▸ Which countries are affected?
The alert applies to Austria.
▸ How serious is this alert?
Serious risk. A serious risk means the product or medicine can cause significant harm. Treat the alert as urgent.
▸ What should I do?
If you take this medicine, contact your pharmacist or prescribing doctor. They can advise on alternative products or substitutes. Do not stop taking prescription medicine without medical advice.
▸ Where can I find the official notice?
The full official notice is published on medikamente.basg.gv.at.

💬 Discussion

Share your experience or ask a question. Real names and email are optional but moderation friendly.

No comments yet — be the first.

We email a confirmation link. Your address stays private.

⚠️ We aggregate official notices. We do not give medical advice. For medical or legal decisions, consult the source agency and a qualified professional.